PP2A: The Wolf in Sheep’s Clothing?
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Protein Phosphatase 2A (PP2A) is a major serine/threonine phosphatase in cells. It consists of a catalytic subunit (C), a structural subunit (A), and a regulatory/variable B-type subunit. PP2A has a critical role to play in homeostasis where its predominant function is as a phosphatase that regulates the major cell signaling pathways in cells. Changes in the assembly, activity and substrate specificity of the PP2A holoenzyme have a direct role in disease and are a major contributor to the maintenance of the transformed phenotype in cancer. We have learned a lot about how PP2A functions from specific mutations that disrupt the core assembly of PP2A and from viral proteins that target PP2A and inhibit its effect as a phosphatase. This prompted various studies revealing that restoration of PP2A activity benefits some cancer patients. However, our understanding of the mechanism of action of this is limited because of the complex nature of PP2A holoenzyme assembly and because it acts through a wide variety of signaling pathways. Information on PP2A is also conflicting as there are situations whereby inactivation of PP2A induces apoptosis in many cancer cells. In this review we discuss this relationship and we also address many of the pertinent and topical questions that relate to novel therapeutic strategies aimed at altering PP2A activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Signaling Through Scaffold, Anchoring, and Adaptor Proteins
Pawson, T., & Scott, J. D. (1997) · Science · doi:10.1126/science.278.5346.2075 · Cited by 2,256
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“…that PP2A walks, and highlights the importance of holoenzyme assembly and the central role being played by the regulatory subunit which regulates the sub-cellular location of PP2A. p53 is a major and extensively studied tumour suppressor protein that is mutated or deleted in many cancers [115].”
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 2×
“Cancerous Inhibitor of PP2A (CIP2A) is a PP2A inhibitor which when over expressed, is associated with poor outcome [75,76].”
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL
Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., Halsey, W., Sathe, G. M., Martin, A.-M., & Gilmer, T. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4490 · Cited by 495 · cited 1×
“Many other mechanisms of laptatinib resistance have been investigated [134,140–144], however the authors of this study suggest that PP2A has potential as a novel biomarker of lapatinib resistance and PP2A inhibition in combination with HER2 inhibition merits further investigation as a potential…”
Structure of the Protein Phosphatase 2A Holoenzyme
Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J. W., Strack, S., Jeffrey, P. D., & Shi, Y. (2006) · Cell · doi:10.1016/j.cell.2006.11.033 · Cited by 450 · cited 1×
“Full activity, specific subcellular location and substrate specification is conferred upon PP2A only when the core dimer interacts with the B regulatory subunit to form a heterotrimeric holoenzyme [22] (Figure 1a).”
PP2A: the expected tumor suppressor
Janssens, V., Goris, J., & Van Hoof, C. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.004 · Cited by 426 · cited 1×
“A large body of work has been done to determine specific functions of known PP2A regulatory subunits and is reviewed extensively [3,12,16,26,27].”
Protein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400 · cited 2×
“Mutations in PP2A subunits have been found in a variety of human cancers and include deletions, point mutations and mutations that generate alternate transcripts [13,33].”
PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)
Janssens, V., Longin, S., & Goris, J. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.004 · Cited by 390 · cited 3×
“As well as this, the PP2A holoenzyme has the ability to interchange B subunits rapidly, allowing PP2A to respond quickly to specific environmental cues [23].”
InfluentialKuo, Y.-C., Huang, K.-Y., Yang, C.-H., Yang, Y.-S., Lee, W.-Y., & Chiang, C.-W. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709585200 · Cited by 367
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 1×
“It is one of the most conserved proteins and together with PP1, is responsible for up to 90% of all serine/threonine activity in a cell [3,8,9].”
Identification of specific PP2A complexes involved in human cell transformation
Chen, W., Possemato, R., Campbell, K. T., Plattner, C. A., Pallas, D. C., & Hahn, W. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00026-1 · Cited by 325 · cited 2×
“ST also displaces PP2A-B55α, PP2A-B56y and PP2A-B56y3 regulatory subunits and when bound to the core subunit, ST will suppress PP2A activity [65].”
Ory, S., Zhou, M., Conrads, T. P., Veenstra, T. D., & Morrison, D. K. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00535-9 · Cited by 296 · cited 3×
“[31,32].”
PP2A: Unveiling a Reluctant Tumor Suppressor
Mumby, M. (2007) · Cell · doi:10.1016/j.cell.2007.06.034 · Cited by 295
Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits
Silverstein, A. M., Barrow, C. A., Davis, A. J., & Mumby, M. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072071699 · Cited by 276
Hemmings, B. A., Adams-Pearson, C., Maurer, F., Mueller, P., Goris, J., Merlevede, W., Hofsteenge, J., & Stone, S. R. (1990) · Biochemistry · doi:10.1021/bi00465a002 · Cited by 243 · cited 1×
“In mammals, the A subunit exists in two isoforms (Aα and Aβ) that share almost 87% sequence identity [14,15].”
Calin, G. A., di Iasio, M. G., Caprini, E., Vorechovsky, I., Natali, P. G., Sozzi, G., Croce, C. M., Barbanti-Brodano, G., Russo, G., & Negrini, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203389 · Cited by 219 · cited 2×
“These mutations result in a decreased binding to other PP2A subunits [35,39].”
Sents, W., Ivanova, E., Lambrecht, C., Haesen, D., & Janssens, V. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08579.x · Cited by 204 · cited 3×
“[ 3,25].”
Molecular cloning of cDNAs encoding two isoforms of the catalytic subunit of protein phosphatase 2A
Stone, S. R., Hofsteenge, J., & Hemmings, B. A. (1987) · Biochemistry · doi:10.1021/bi00397a003 · Cited by 168
Phosphorylation of mammalian Sgo2 by Aurora B recruits PP2A and MCAK to centromeres
Tanno, Y., Kitajima, T. S., Honda, T., Ando, Y., Ishiguro, K.-I., & Watanabe, Y. (2010) · Genes & Development · doi:10.1101/gad.1945310 · Cited by 139
Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139 · cited 1×
“Many other mechanisms of laptatinib resistance have been investigated [134,140–144], however”
Adams, D. G., Coffee, R. L., Zhang, H., Pelech, S., Strack, S., & Wadzinski, B. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502464200 · Cited by 133 · cited 2×
“[31,32].”
Ruediger, R., Ruiz, J., & Walter, G. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05744-11 · Cited by 98 · cited 2×
“Mice expressing the E64D mutation demonstrated increased incidence of p53 dependant lung cancer [40].”
ZHOU, J., PHAM, H. T., RUEDIGER, R., & WALTER, G. (2003) · Biochemical Journal · doi:10.1042/bj20021244 · Cited by 95 · cited 1×
“Aα and Aβ are detected primarily in the cytoplasm but differ in their ability to bind to the B regulatory subunits [17].”
Cheng, Y., Liu, W., Kim, S.-T., Sun, J., Lu, L., Sun, J., Zheng, S. L., Isaacs, W. B., & Xu, J. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.05.002 · Cited by 64 · cited 1×
“PP2A B subunit mutations are less frequent, but some deletion mutations have been identified in breast, prostate and ovarian cancers [33,45–47].”
Cited by
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143
McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0123 · Cited by 78
“PP2A dephosphorylates a large number of critical oncogenic proteins including Akt, Erk, c-MYC, Bcl-2, and others (4).”
Background
Metadata
- Authors
- Kiely, M., & Kiely, P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2015-04-10
- Volume
- 7
- Issue
- 2
- Pages
- 648-669
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2111742556
- Cited by
- 78
- References
- 27
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.